At the news
? BULLISHIMPACT 6/10 6-K filed Nov 2, 2026 at 06:06 ET
HUTCHMED announced that regulatory filings for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in MET-driven EGFR-mutated lung cancer have been accepted for review by the EMA in Europe and the MHLW in Japan, following a US FDA NDA submission in September 2026. The filings are supported by positive SAFFRON Phase III data showing statistically significant improvements in progression-free survival and overall survival versus chemotherapy. This expands the global regulatory pathway for the combination, which is already approved in China and temporarily authorized in Switzerland.
- EMA validated and accepted MAA for ORPATHYS plus TAGRISSO in Europe for MET-overexpressed/amplified NSCLC after EGFR-TKI progression.
- Japan MHLW accepted NDA for same combination in unresectable, advanced or recurrent NSCLC with MET overexpression/amplification after EGFR-TKI therapy.
- US FDA NDA for the combination was submitted in September 2026.
- SAFFRON Phase III trial showed PFS HR 0.55 (p<0.001), median PFS 7.6 vs 5.4 months; OS HR 0.68 (p=0.010), median OS 17.8 vs 12.9 months.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access